drugset / Trial / NCT01090973
Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
Phase 2
Terminated
1 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to find out the effects and the safety of an investigational study drug called LBH589 when given to people with relapsed or refractory chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).
Timeline
- Start
- 2010-03
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 40 mg | Oral |